Brokerages expect IntriCon Co. (NASDAQ:IIN) to post $30.05 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for IntriCon’s earnings. The highest sales estimate is $30.70 million and the lowest is $29.40 million. IntriCon reported sales of $25.36 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 18.5%. The firm is scheduled to announce its next earnings results on Monday, May 6th.
On average, analysts expect that IntriCon will report full year sales of $130.95 million for the current year, with estimates ranging from $130.30 million to $131.59 million. For the next year, analysts expect that the firm will report sales of $160.69 million, with estimates ranging from $156.00 million to $165.37 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for IntriCon.
IntriCon (NASDAQ:IIN) last released its quarterly earnings data on Tuesday, February 19th. The technology company reported $0.09 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.07). The firm had revenue of $30.81 million during the quarter, compared to analyst estimates of $30.30 million. IntriCon had a return on equity of 9.63% and a net margin of 4.76%.
In other news, VP Greg Gruenhagen sold 1,500 shares of the company’s stock in a transaction on Monday, February 4th. The stock was sold at an average price of $26.21, for a total value of $39,315.00. Following the completion of the sale, the vice president now owns 4,049 shares in the company, valued at $106,124.29. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders have sold 7,500 shares of company stock valued at $198,225. 11.50% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of IntriCon by 3.4% in the 4th quarter. BlackRock Inc. now owns 509,049 shares of the technology company’s stock worth $13,428,000 after purchasing an additional 16,512 shares in the last quarter. Vanguard Group Inc grew its position in IntriCon by 66.1% in the third quarter. Vanguard Group Inc now owns 467,907 shares of the technology company’s stock worth $26,296,000 after buying an additional 186,222 shares during the last quarter. Vanguard Group Inc. grew its position in IntriCon by 66.1% in the third quarter. Vanguard Group Inc. now owns 467,907 shares of the technology company’s stock worth $26,296,000 after buying an additional 186,222 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of IntriCon by 11.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 343,667 shares of the technology company’s stock valued at $9,066,000 after buying an additional 34,031 shares in the last quarter. Finally, Bamco Inc. NY increased its holdings in shares of IntriCon by 61.2% in the third quarter. Bamco Inc. NY now owns 169,217 shares of the technology company’s stock valued at $9,510,000 after buying an additional 64,217 shares in the last quarter. 64.83% of the stock is currently owned by institutional investors.
IntriCon stock traded down $0.44 during midday trading on Monday, reaching $26.13. 121,800 shares of the stock traded hands, compared to its average volume of 172,969. IntriCon has a fifty-two week low of $18.85 and a fifty-two week high of $76.80. The firm has a market capitalization of $227.24 million, a price-to-earnings ratio of 40.83, a PEG ratio of 3.34 and a beta of 1.21.
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.
Featured Article: Are all No-Load Funds Equal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.